PT3677591T - Anticorpos anti-cd38 e fusões a interferão alfa-2b atenuado - Google Patents
Anticorpos anti-cd38 e fusões a interferão alfa-2b atenuadoInfo
- Publication number
- PT3677591T PT3677591T PT192130300T PT19213030T PT3677591T PT 3677591 T PT3677591 T PT 3677591T PT 192130300 T PT192130300 T PT 192130300T PT 19213030 T PT19213030 T PT 19213030T PT 3677591 T PT3677591 T PT 3677591T
- Authority
- PT
- Portugal
- Prior art keywords
- fusions
- antibodies
- interferon alpha
- attenuated interferon
- attenuated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13721243.7A EP2992013B1 (en) | 2013-04-29 | 2013-04-29 | Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b |
| PCT/US2013/038659 WO2014178820A1 (en) | 2013-04-29 | 2013-04-29 | Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b |
| EP19213030.0A EP3677591B1 (en) | 2013-04-29 | 2013-04-29 | Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3677591T true PT3677591T (pt) | 2023-02-17 |
Family
ID=48325957
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT137212437T PT2992013T (pt) | 2013-04-29 | 2013-04-29 | Anticorpos anti-cd38 e fusões a interferão alfa-2b atenuado |
| PT192130300T PT3677591T (pt) | 2013-04-29 | 2013-04-29 | Anticorpos anti-cd38 e fusões a interferão alfa-2b atenuado |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT137212437T PT2992013T (pt) | 2013-04-29 | 2013-04-29 | Anticorpos anti-cd38 e fusões a interferão alfa-2b atenuado |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US9963515B2 (pt) |
| EP (2) | EP3677591B1 (pt) |
| JP (1) | JP6286532B2 (pt) |
| KR (1) | KR102094022B1 (pt) |
| CN (2) | CN105473615B (pt) |
| AU (2) | AU2013388126B2 (pt) |
| BR (1) | BR112015027313A2 (pt) |
| CA (1) | CA2909952C (pt) |
| DK (1) | DK3677591T5 (pt) |
| EA (1) | EA033115B1 (pt) |
| ES (2) | ES2938708T3 (pt) |
| FI (1) | FI3677591T3 (pt) |
| HK (1) | HK1216650A1 (pt) |
| IL (1) | IL242296B (pt) |
| MX (1) | MX370377B (pt) |
| NZ (1) | NZ713641A (pt) |
| PH (1) | PH12015502439A1 (pt) |
| PL (2) | PL3677591T3 (pt) |
| PT (2) | PT2992013T (pt) |
| SG (1) | SG11201508923VA (pt) |
| UA (1) | UA113129C2 (pt) |
| WO (1) | WO2014178820A1 (pt) |
| ZA (1) | ZA201507789B (pt) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102096224B1 (ko) | 2011-10-28 | 2020-04-03 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | 폴리펩티드 구축물 및 이의 용도 |
| CN104470536A (zh) | 2012-03-03 | 2015-03-25 | 免疫基因公司 | 工程化的抗体-干扰素突变体融合分子 |
| EP2900232B1 (en) | 2012-09-25 | 2017-11-15 | MorphoSys AG | Combinations and uses thereof |
| MX370377B (es) | 2013-04-29 | 2019-12-11 | Teva Pharmaceuticals Australia Pty Ltd | Anticuerpos anti-cd38 y fusiones con interferón alfa-2b atenuado. |
| US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
| US9603927B2 (en) * | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
| WO2016040294A2 (en) | 2014-09-09 | 2016-03-17 | Janssen Biotech, Inc. | Combination therapies with anti-cd38 antibodies |
| JP6730271B2 (ja) | 2014-10-29 | 2020-07-29 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | インターフェロンα２Ｂバリアント |
| CA2969717A1 (en) | 2014-12-04 | 2016-06-09 | Janssen Biotech, Inc. | Anti-cd38 antibodies for treatment of acute myeloid leukemia |
| BR112017024877A2 (pt) | 2015-05-20 | 2019-09-17 | Janssen Biotech, Inc. | anticorpo anti-cd38 e seu uso no tratamento de amiloidose de cadeia leve e outras malignidades hematológicas positivas para cd38 |
| MX2018000265A (es) | 2015-06-22 | 2018-05-23 | Janssen Biotech Inc | Terapias de combinacion para enfermedades malignas hematologicas con anticuerpos anti-cd38 e inhibidores de survivina. |
| MD3313441T2 (ro) | 2015-06-24 | 2024-08-31 | Janssen Biotech Inc | Modularea imună și tratament al tumorilor solide cu anticorpi care leagă specific CD38 |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| US20180155411A1 (en) * | 2015-07-08 | 2018-06-07 | The Board Of Trustees Of The Leland Stanford Junior University | Heterotypic antibodies specific for human rotavirus |
| PE20181365A1 (es) | 2015-11-03 | 2018-08-27 | Janssen Biotech Inc | Formulaciones subcutaneas de anticuerpos anti-cd38 y sus usos |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| SG11201806214RA (en) | 2016-03-04 | 2018-08-30 | Morphosys Ag | Clinical assessment of m-protein response in multiple myeloma |
| EP3474895A1 (en) | 2016-06-28 | 2019-05-01 | UMC Utrecht Holding B.V. | TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38 |
| WO2018014068A1 (en) * | 2016-07-19 | 2018-01-25 | Teva Pharmaceuticals Australia Pty Ltd | Attenuated type i ifn cd47 combination therapy |
| JP7241677B2 (ja) * | 2016-07-19 | 2023-03-17 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | 抗ｃｄ４７併用療法 |
| WO2018015498A1 (en) | 2016-07-20 | 2018-01-25 | Hybrigenics Sa | Combinations of inecalcitol with an anti-cd38 agent and their uses for treating cancer |
| CA3031028C (en) * | 2016-07-25 | 2024-02-13 | Lu Wang | Affinity chromatography wash buffer |
| US11426706B2 (en) | 2017-06-21 | 2022-08-30 | Cephalon, Inc. | Cation exchange chromatography wash buffer |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| WO2019089832A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
| JP6648171B2 (ja) * | 2018-02-02 | 2020-02-14 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | 抗ｃｄ３８抗体及び弱毒化インターフェロンアルファ−２ｂとの融合物 |
| MA53920A (fr) | 2018-10-17 | 2021-09-15 | Janssen Biotech Inc | Procédé de fourniture d'administration sous-cutanée d'anticorps anti-cd38 |
| CA3122902A1 (en) | 2018-12-14 | 2020-06-18 | Morphosys Ag | Antibody formulations |
| WO2020154540A1 (en) * | 2019-01-23 | 2020-07-30 | Millennium Pharmaceuticals, Inc. | Anti-cd38 antibodies |
| PE20221465A1 (es) | 2020-01-13 | 2022-09-21 | Denali Therapeutics Inc | Anticuerpos anti-trem2 y metodos para utilizarlos |
| BR112022016216A2 (pt) * | 2020-02-16 | 2023-02-28 | Aulos Bioscience Inc | Anticorpos anti-il-2 modificados |
| US20220275090A1 (en) | 2021-02-22 | 2022-09-01 | Janssen Biotech, Inc. | Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors |
| AU2022325383A1 (en) * | 2021-08-12 | 2024-02-15 | Shanghai Jmt-Bio Technology Co., Ltd. | GPC3-TARGETED ANTIBODY INTERFERON α FUSION PROTEIN AND USE THEREOF |
| IL312514A (en) | 2021-11-03 | 2024-07-01 | Janssen Biotech Inc | Corticosteroid reduction in treatment with anti-CD38 antibodies |
| WO2023144303A1 (en) | 2022-01-31 | 2023-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Cd38 as a biomarker and biotarget in t-cell lymphomas |
| WO2023223100A1 (en) * | 2022-05-18 | 2023-11-23 | Takeda Pharmaceutical Company Limited | Anti-cd38 fusion protein formulation |
| TW202423968A (zh) * | 2022-09-29 | 2024-06-16 | 日商武田藥品工業股份有限公司 | Ｃｄ３８結合融合蛋白組合療法 |
Family Cites Families (107)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2148299B (en) | 1983-09-01 | 1988-01-06 | Hybritech Inc | Antibody compositions of therapeutic agents having an extended serum half-life |
| US4908431A (en) | 1986-01-22 | 1990-03-13 | Temple University-Of The Commonwealth System Of Higher Education | Monoclonal antibodies to human kininogen and methods of preparing same |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| US5846534A (en) | 1988-02-12 | 1998-12-08 | British Technology Group Limited | Antibodies to the antigen campath-1 |
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| ES2052027T5 (es) | 1988-11-11 | 2005-04-16 | Medical Research Council | Clonacion de secuencias de dominio variable de inmunoglobulina. |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5976531A (en) | 1990-04-19 | 1999-11-02 | The Dow Chemical Company | Composite antibodies of human subgroup IV light chain capable of binding to tag-72 |
| GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
| US5650150A (en) | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
| US5558864A (en) | 1991-03-06 | 1996-09-24 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Humanized and chimeric anti-epidermal growth factor receptor monoclonal antibodies |
| DK0628639T3 (da) | 1991-04-25 | 2000-01-24 | Chugai Pharmaceutical Co Ltd | Rekonstitueret humant antistof mod human interleukin-6-receptor |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US6042828A (en) | 1992-09-07 | 2000-03-28 | Kyowa Hakko Kogyo Co., Ltd. | Humanized antibodies to ganglioside GM2 |
| CA2126967A1 (en) | 1992-11-04 | 1994-05-11 | Anna M. Wu | Novel antibody construct |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| HU221001B1 (hu) | 1994-03-17 | 2002-07-29 | Merck Patent Gmbh. | Egyláncú anti-EGFR Fv-k és anti-EGFR ellenanyagok |
| DE69523857T2 (de) | 1994-09-16 | 2002-06-13 | Merck Patent Gmbh | Immunokonjugate |
| US20020164788A1 (en) * | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
| WO1997000271A1 (en) | 1995-06-14 | 1997-01-03 | The Regents Of The University Of California | Novel high affinity human antibodies to tumor antigens |
| DE69621940T2 (de) | 1995-08-18 | 2003-01-16 | Morphosys Ag | Protein-/(poly)peptidbibliotheken |
| US5723125A (en) | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
| HUP9901562A3 (en) | 1996-05-04 | 2000-06-28 | Astrazeneca Ab | Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system |
| US6417337B1 (en) | 1996-10-31 | 2002-07-09 | The Dow Chemical Company | High affinity humanized anti-CEA monoclonal antibodies |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6872568B1 (en) | 1997-03-17 | 2005-03-29 | Human Genome Sciences, Inc. | Death domain containing receptor 5 antibodies |
| EP1012184B1 (en) | 1997-07-14 | 2007-10-10 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins |
| AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
| EP1071700B1 (en) | 1998-04-20 | 2010-02-17 | GlycArt Biotechnology AG | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| CA2343094A1 (en) | 1998-10-16 | 2000-04-27 | Biogen, Inc. | Interferon-beta fusion proteins and uses |
| CA2354377C (en) | 1998-12-09 | 2007-04-10 | Tatsuji Seki | A method for manufacturing glycoproteins having human-type glycosylation |
| US7223397B1 (en) | 1999-01-07 | 2007-05-29 | Research Development Foundation | Potentiation of anti-CD38-Immunotoxin cytotoxicity |
| EP1141024B1 (en) | 1999-01-15 | 2018-08-08 | Genentech, Inc. | POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION |
| JP4778617B2 (ja) | 1999-03-12 | 2011-09-21 | ジョージタウン ユニバーシティ | マトリプターゼ、セリンプロテアーゼおよびその応用 |
| US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| AU4314801A (en) | 2000-02-11 | 2001-08-20 | Lexigen Pharm Corp | Enhancing the circulating half-life of antibody-based fusion proteins |
| US7063845B2 (en) | 2000-04-28 | 2006-06-20 | Gemini Science, Inc. | Human anti-CD40 antibodies |
| US7521047B2 (en) | 2000-05-12 | 2009-04-21 | Gpc Biotech Ag | Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells |
| EP1292334A4 (en) * | 2000-06-22 | 2003-11-19 | Idec Pharma Corp | BISPECIFIC FUSION PROTEIN AND METHOD FOR USE TO ENHANCE THE KILLING OF TARGET CELLS BY EFFECTOR CELLS |
| EP2322644A1 (en) | 2000-06-28 | 2011-05-18 | GlycoFi, Inc. | Methods for producing modified glycoproteins |
| EP1174440A1 (en) | 2000-07-19 | 2002-01-23 | U-BISys B.V. | A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment |
| DE60143544D1 (de) | 2000-12-12 | 2011-01-05 | Medimmune Llc | Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung |
| HUP0302525A2 (hu) | 2001-01-05 | 2003-10-28 | Abgenix, Inc. | Az inzulinszerű növekedési faktor I receptor elleni ellenanyagok |
| FR2823764B1 (fr) | 2001-04-24 | 2003-12-12 | Genodyssee | Nouveaux polynucleotides et polypeptides du gene ifn alpha-17 |
| US20020193569A1 (en) | 2001-06-04 | 2002-12-19 | Idec Pharmaceuticals Corporation | Bispecific fusion protein and method of use for enhancing effector cell killing of target cells |
| DK1409544T3 (da) | 2001-07-03 | 2009-10-26 | Genentech Inc | Humane DR4-antistoffer og anvendelser deraf |
| AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
| AR035119A1 (es) | 2001-08-16 | 2004-04-14 | Lilly Co Eli | Anticuerpos humanos antagonistas anti-htnfsf13b |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| CA2471702C (en) | 2002-01-09 | 2013-03-19 | Medarex, Inc. | Human monoclonal antibodies against cd30 |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| JP4472351B2 (ja) | 2002-03-01 | 2010-06-02 | イミューノメディクス、インコーポレイテッド | インターナライジング抗ｃｄ７４抗体およびその使用方法 |
| US7332580B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
| US7202346B2 (en) | 2002-07-03 | 2007-04-10 | Immunogen Inc. | Antibodies to non-shed Muc1 and Muc16, and uses thereof |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US7534427B2 (en) * | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
| JP2007524351A (ja) | 2003-02-18 | 2007-08-30 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 改良された特性を有するインターフェロンアルファムテインの融合タンパク質 |
| US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
| DE10343708A1 (de) | 2003-09-18 | 2005-05-12 | Nexpress Solutions Llc | Verfahren für das Befestigen von Toner an einem Bedruckstoff und Mikrowelleneinrichtung |
| EP1844815B1 (en) | 2003-11-04 | 2011-09-14 | Novartis Vaccines and Diagnostics, Inc. | Combination therapy comprising anti-CD20 and anti-CD40 antibodies for the treatment of B cell-related cancers |
| MXPA06008700A (es) | 2004-02-06 | 2007-01-19 | Morphosys Ag | Anticuerpos anti-cd38 humanos y usos para los mismos. |
| WO2005103083A2 (en) * | 2004-02-06 | 2005-11-03 | Morphosys Ag | Anti-cd38 human antibodies and uses therefor |
| US8034352B2 (en) | 2005-04-06 | 2011-10-11 | Ibc Pharmaceuticals, Inc. | Tetrameric cytokines with improved biological activity |
| US7273608B2 (en) | 2004-03-11 | 2007-09-25 | City Of Hope | Humanized anti-CEA T84.66 antibody and uses thereof |
| US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| CA2601417C (en) | 2004-07-01 | 2018-10-30 | Novo Nordisk A/S | Human anti-kir antibodies |
| JP5222559B2 (ja) | 2004-10-15 | 2013-06-26 | シアトル ジェネティックス， インコーポレイテッド | 癌および免疫障害の処置および予防のための抗ｃｄ７０抗体ならびにその使用 |
| MX2007011064A (es) | 2005-03-23 | 2008-02-19 | Genmab As | Anticuerpos contra cd38 para tratamiento de mieloma multiple. |
| TW200745162A (en) | 2005-05-24 | 2007-12-16 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 |
| JP2008545409A (ja) | 2005-05-26 | 2008-12-18 | シェーリング コーポレイション | インターフェロン−ＩｇＧ融合体 |
| JP5208733B2 (ja) | 2005-06-29 | 2013-06-12 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | 組換えインターフェロンα２（ＩＦＮα２）変異体 |
| EA021669B1 (ru) | 2005-07-18 | 2015-08-31 | Амджен Инк. | Нейтрализующие антитела человека против b7rp1 |
| AU2006294663B2 (en) | 2005-09-26 | 2012-03-22 | Medarex, Inc. | Human monoclonal antibodies to CD70 |
| CN103554259B (zh) | 2005-10-12 | 2016-05-18 | 莫佛塞斯公司 | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 |
| WO2007053718A1 (en) | 2005-10-31 | 2007-05-10 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health | Antibodies and immunotoxins that target human glycoprotein nmb |
| GB0525214D0 (en) | 2005-12-12 | 2006-01-18 | Bioinvent Int Ab | Biological materials and uses thereof |
| CN101045156B (zh) | 2006-03-29 | 2012-05-02 | 刘宏利 | 特异靶向性药物及其用途 |
| EP1878747A1 (en) | 2006-07-11 | 2008-01-16 | greenovation Biotech GmbH | Glyco-engineered antibodies |
| CA2660795C (en) * | 2006-09-18 | 2014-11-18 | Xencor, Inc. | Optimized antibodies that target hm1.24 |
| TR201910145T4 (tr) | 2006-09-26 | 2019-08-21 | Genmab As | Tümörlerin tedavi edilmesine yönelik anti-CD38 artı kortikosteroidler artı bir kortikosteroid-olmayan kemoterapötik. |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| US11535673B2 (en) | 2007-04-05 | 2022-12-27 | President and Fellows of Harvard CoHege | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
| TW200902554A (en) | 2007-05-08 | 2009-01-16 | Genentech Inc | Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates |
| WO2008145139A1 (en) | 2007-05-31 | 2008-12-04 | Genmab A/S | Fusion or linked proteins with extended half life |
| AU2008282729B2 (en) | 2007-08-01 | 2015-07-16 | Scott & White Healthcare | A fold-back diabody diphtheria toxin immunotoxin and methods of use |
| US20090076249A1 (en) | 2007-09-19 | 2009-03-19 | Michel De Weers | Antibodies against CD38 for treatment of multiple myeloma |
| BRPI0817108B8 (pt) | 2007-09-21 | 2021-05-25 | Univ California | composição compreendendo uma proteína de fusão, kit compreendendo a referida composição e uso da mesma. |
| US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| PL2238168T3 (pl) | 2007-12-26 | 2014-11-28 | Biotest Ag | Środki które mają za cel CD138 i ich zastosowania |
| EP2313435A4 (en) | 2008-07-01 | 2012-08-08 | Aveo Pharmaceuticals Inc | FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS |
| EP2408820A4 (en) | 2009-03-16 | 2013-01-23 | Cephalon Australia Pty Ltd | HUMANIZED ANTIBODIES WITH ANTITUMOR EFFECT |
| RS59769B1 (sr) * | 2010-06-09 | 2020-02-28 | Genmab As | Antitela protiv humanog cd38 |
| LT2621531T (lt) | 2010-09-27 | 2017-04-10 | Morphosys Ag | Anti-cd38 antikūnas ir lenalidomidas arba bortezomibas, skirti išsėtinės mielomos ir nhl (nehodžino limfoma) gydymui |
| PT2654790T (pt) | 2010-12-22 | 2019-05-16 | Teva Pharmaceuticals Australia Pty Ltd | Anticorpo modificado com semivida melhorada |
| JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| KR102096224B1 (ko) * | 2011-10-28 | 2020-04-03 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | 폴리펩티드 구축물 및 이의 용도 |
| JP6416628B2 (ja) | 2012-01-20 | 2018-10-31 | ブイアイビー ブイゼットダブリュＶｉｂ Ｖｚｗ | 標的変異体αヘリックスバンドルサイトカイン |
| CN104470536A (zh) | 2012-03-03 | 2015-03-25 | 免疫基因公司 | 工程化的抗体-干扰素突变体融合分子 |
| WO2014028502A1 (en) | 2012-08-13 | 2014-02-20 | ImmunGene Inc. | Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases |
| MX370377B (es) | 2013-04-29 | 2019-12-11 | Teva Pharmaceuticals Australia Pty Ltd | Anticuerpos anti-cd38 y fusiones con interferón alfa-2b atenuado. |
| UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
| JP6730271B2 (ja) | 2014-10-29 | 2020-07-29 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | インターフェロンα２Ｂバリアント |
-
2013
- 2013-04-29 MX MX2015015043A patent/MX370377B/es active IP Right Grant
- 2013-04-29 CA CA2909952A patent/CA2909952C/en active Active
- 2013-04-29 ES ES19213030T patent/ES2938708T3/es active Active
- 2013-04-29 EP EP19213030.0A patent/EP3677591B1/en active Active
- 2013-04-29 AU AU2013388126A patent/AU2013388126B2/en active Active
- 2013-04-29 PL PL19213030.0T patent/PL3677591T3/pl unknown
- 2013-04-29 PT PT137212437T patent/PT2992013T/pt unknown
- 2013-04-29 CN CN201380076093.XA patent/CN105473615B/zh active Active
- 2013-04-29 WO PCT/US2013/038659 patent/WO2014178820A1/en active Application Filing
- 2013-04-29 EA EA201592076A patent/EA033115B1/ru not_active IP Right Cessation
- 2013-04-29 PL PL13721243T patent/PL2992013T3/pl unknown
- 2013-04-29 FI FIEP19213030.0T patent/FI3677591T3/fi active
- 2013-04-29 CN CN201910277311.5A patent/CN110526971B/zh active Active
- 2013-04-29 JP JP2016511712A patent/JP6286532B2/ja active Active
- 2013-04-29 PT PT192130300T patent/PT3677591T/pt unknown
- 2013-04-29 BR BR112015027313A patent/BR112015027313A2/pt not_active Application Discontinuation
- 2013-04-29 ES ES13721243T patent/ES2774976T3/es active Active
- 2013-04-29 KR KR1020157031108A patent/KR102094022B1/ko active IP Right Grant
- 2013-04-29 UA UAA201511753A patent/UA113129C2/uk unknown
- 2013-04-29 NZ NZ713641A patent/NZ713641A/en unknown
- 2013-04-29 DK DK19213030.0T patent/DK3677591T5/da active
- 2013-04-29 SG SG11201508923VA patent/SG11201508923VA/en unknown
- 2013-04-29 EP EP13721243.7A patent/EP2992013B1/en active Active
-
2015
- 2015-10-19 ZA ZA2015/07789A patent/ZA201507789B/en unknown
- 2015-10-22 PH PH12015502439A patent/PH12015502439A1/en unknown
- 2015-10-26 US US14/922,282 patent/US9963515B2/en active Active
- 2015-10-27 IL IL242296A patent/IL242296B/en active IP Right Grant
-
2016
- 2016-04-25 HK HK16104726.5A patent/HK1216650A1/zh unknown
-
2019
- 2019-06-07 AU AU2019204016A patent/AU2019204016B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL242296B (en) | Antibodies against cd38 and fusions to attenuated interferon alpha-2b | |
| IL261743B (en) | and their uses 33–il antibodies against | |
| IL269226A (en) | Antibodies that bind to TL1A and uses thereof | |
| IL261547B (en) | Antibodies against pesidine and their uses | |
| HK1214969A1 (zh) | 抗- -β抗體及其使用 | |
| IL243974B (en) | Antibodies against –prlr and uses | |
| ZA201508896B (en) | Anti-c10orf54 antibodies and uses thereof | |
| IL240443A0 (en) | Antibodies against tnf-a with a high level of galactosylation and their uses | |
| SG11201509116VA (en) | Anti-tweakr antibodies and uses thereof |